Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy
CDC on Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy in the news
Blogs on Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Risk calculators and risk factors for Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.